Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Agrin and Perlecan Mediate Tumorigenic Processes in Oral Squamous Cell Carcinoma

Full text
Show less -
Kawahara, Rebeca [1] ; Granato, Daniela C. [1] ; Carnielli, Carolina M. [1] ; Cervigne, Nilva K. [2] ; Oliveria, Carine E. [2] ; Martinez, Cesar A. R. [1] ; Yokoo, Sami [1] ; Fonseca, Felipe P. [2] ; Lopes, Marcio [2] ; Santos-Silva, Alan R. [2] ; Graner, Edgard [2] ; Coletta, Ricardo D. [2] ; Paes Leme, Adriana Franco [1]
Total Authors: 13
[1] CNPEM, Lab Nacl Biociencias, Lab Espectrometria Massas, Campinas, SP - Brazil
[2] Univ Estadual Campinas, UNICAMP, Fac Odontol Piracicaba, Piracicaba - Brazil
Total Affiliations: 2
Document type: Journal article
Source: PLoS One; v. 9, n. 12 DEC 15 2014.
Web of Science Citations: 23

Oral squamous cell carcinoma is the most common type of cancer in the oral cavity, representing more than 90% of all oral cancers. The characterization of altered molecules in oral cancer is essential to understand molecular mechanisms underlying tumor progression as well as to contribute to cancer biomarker and therapeutic target discovery. Proteoglycans are key molecular effectors of cell surface and pericellular microenvironments, performing multiple functions in cancer. Two of the major basement membrane proteoglycans, agrin and perlecan, were investigated in this study regarding their role in oral cancer. Using real time quantitative PCR (qRT-PCR), we showed that agrin and perlecan are highly expressed in oral squamous cell carcinoma. Interestingly, cell lines originated from distinct sites showed different expression of agrin and perlecan. Enzymatically targeting chondroitin sulfate modification by chondroitinase, oral squamous carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins and increased sensibility to cisplatin. Additionally, knockdown of agrin and perlecan promoted a decrease on cell migration and adhesion, and on resistance of cells to cisplatin. Our study showed, for the first time, a negative regulation on oral cancer-associated events by either targeting chondroitin sulfate content or agrin and perlecan levels. (AU)

FAPESP's process: 09/54067-3 - Acquisition of a mass spectrometer coupled to a liquid chromatography system for increasing the capacity to meet the needs of users and for making new technologies available in the Laboratory of Mass Spectrometry
Grantee:Adriana Franco Paes Leme
Support type: Multi-user Equipment Program
FAPESP's process: 11/22421-2 - Determination of cleavage sites of recombinant ADAM-17 in human cells
Grantee:Rebeca Kawahara Sakuma
Support type: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 10/19278-0 - Study of regulation of ADAMs in oral cancer
Grantee:Adriana Franco Paes Leme
Support type: Research Grants - Young Investigators Grants